Pradaxa has also been approved to reduce the risk of recurrent venous thromboembolism patients who have previously been treated.
In clinical trials, Pradaxa demonstrated a 92 percent reduction of risk of recurrent blood clots compared to a placebo, according to the news release.
More Articles on FDA Approvals:
FDA Clears Intuitive Surgical’s Latest da Vinci Robot Upgrade
FDA Approves Alprolix for Hemophilia B Treatment
FDA Approves Otezla for Psoriatic Arthritis Treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
